text:
Q: Singleton with Entity Framework : Will Queries run multiple times? With a model such as ...
using System;
using System.Collections.Generic;
using System.Linq;
using System.Text;
using System.Data.Entity.ModelConfiguration;
using System.Data.Entity;
using System.Data.Entity.Infrastructure;
using System.ComponentModel.DataAnnotations;

namespace Singleton
{
    public class Program
    {
        public static void Main(string[] args)
        {
            var builder = new ModelBuilder();

            builder.Configurations.Add(new TemplateConfiguration());
            builder.Configurations.Add(new UserConfiguration());
            builder.Configurations.Add(new UnitConfiguration());
            builder.Configurations.Add(new AttributeConfiguration());

            var model = builder.CreateModel();

            using (var context = new SampleDataContext(model))
            {
                bool updating = true;
                if (updating)
                {
                    var units = new List<Unit>
                {
                    new Unit{ Name = "Unit1" },
                    new Unit{ Name = "Unit2" }
                };

                    units.ForEach(x => { context.Units.Add(x); });
                    context.SaveChanges();

                    var templates = new List<Template>
                {
                    new Template{
                        Name = "Default",
                        Attributes = new List<Attribute>
                        {
                            new Attribute
                            {
                                Unit = context.Units.Single( i => i.Name == "Unit1" )
                            }
                        }
                    }
                };

                    templates.ForEach(x =>
                    {
                        context.Templates.Add(x);
                    });
                    context.SaveChanges();
                    var users = new List<User>
                {
                    new User
                    {
                        Name = "Stacey"
                    },
                    new User
                    {
                        Name = "Daniel"
                    },
                    new User
                    {
                        Name = "Derek"
                    }
                };

                    users.ForEach(x => { context.Users.Add(x); });
                    context.SaveChanges();

                    updating = !updating; // stop updating
                }

                if (!updating)
                {
                    Single.Instance = context.Templates.Single(i => i.Name == "Default");
                }

                foreach (User user in context.Users)
                {
                    Console.WriteLine(user.Template.Name); // does template requery?
                }
            }
        }
    }
    public class Template
    {
        public virtual int Id { get; set; }
        public virtual string Name { get; set; }
        public virtual ICollection<Attribute> Attributes { get; set; }
    }

    public class TemplateConfiguration : EntityConfiguration<Template>
    {
        public TemplateConfiguration()
        {
            HasKey(k => k.Id);
            Property(k => k.Id).IsIdentity();
            Property(k => k.Name);

            //// map the collection entity
            HasMany(k => k.Attributes).WithRequired()
                .Map("template.attributes",
                    (template, attribute) => new
                    {
                        Template = template.Id,
                        Attribute = attribute.Id
                    });

            MapSingleType(c => new
            {
                c.Id,
                c.Name
            }).ToTable("templates");
        }
    }

    public class User
    {
        public virtual int Id { get; set; }
        public virtual string Name { get; set; }

        [StoreGenerated(StoreGeneratedPattern.None)]
        public Template Template { get { return Single.Instance; } }
    }

    public class UserConfiguration : EntityConfiguration<User>
    {
        public UserConfiguration()
        {
            HasKey(k => k.Id);
            Property(k => k.Id).IsIdentity();
            Property(k => k.Name);

            MapSingleType(c => new
            {
                c.Id,
                c.Name
            }).ToTable("users");
        }
    }

    public class Unit
    {
        public virtual int Id { get; set; }
        public virtual string Name { get; set; }
    }

    public class UnitConfiguration : EntityConfiguration<Unit>
    {
        public UnitConfiguration()
        {
            HasKey(k => k.Id);
            Property(k => k.Id).IsIdentity();
            Property(k => k.Name);

            MapSingleType(c => new
            {
                c.Id,
                c.Name
            }).ToTable("units");
        }
    }

    public class Attribute
    {
        public virtual int Id { get; set; }
        public Unit Unit { get; set; }
    }

    public class AttributeConfiguration : EntityConfiguration<Attribute>
    {
        public AttributeConfiguration()
        {
            HasKey(k => k.Id);
            Property(k => k.Id).IsIdentity();
            // Initialize the Statistic
            HasRequired(k => k.Unit);

            // map the data type to the context so that it can be queried.
            MapHierarchy(c => new
            {
                c.Id,
                Unit = c.Unit.Id
            }).ToTable("attributes");
        }
    }
    public class Single
    {
        public static Template Instance;
    }

    public class SampleDataContext : DbContext
    {
        public SampleDataContext(DbModel model)
            : base(model)
        {
            this.ObjectContext.ContextOptions.LazyLoadingEnabled = true;
        }

        protected override void OnModelCreating(ModelBuilder modelBuilder)
        {
            base.OnModelCreating(modelBuilder);
        }

        public DbSet<Template> Templates { get; set; }
        public DbSet<User> Users { get; set; }
        public DbSet<Unit> Units { get; set; }
        public DbSet<Attribute> Attributes { get; set; }
    }
}

if I assign Singleton.Instance to a query from the DataContext, and then assign the Singleton.Instance to other objects in my code, will the SQL be run once, or each time it is accessed? Can anyone help me here to see if this pattern is going to save some SQL?

A: The SQL will run each time you access it.
What you'r looking for is some kind of caching strategy.
Have a look at the following thread. I think it will help you: How to make Entity Framework cache some objects

A: From context.SomeQuery, you're almost certainly just returning some kind of queryable object or other iterable (I'm not sure your example reflects how your EF solution is actually architected, I think some elements were lost for the sake of brevity).  So, every time you access this singleton, you're just going to iterate over it (run the query) again.
I recommend you use a simple memoization revolving around 4.0 caching, try this.


text:
Career at WUR
Join us and start your career at Wageningen University & Research. We would be very proud to welcome you as our new employee in Wageningen or in one of our 32 locations.
At WUR, we are always looking for talented colleagues who want to work on improving the quality of life.
Why choose WUR?
In its more than 100-year history, Wageningen University & Research has grown into the centre of state-of-the-art knowledge about food and the natural environment. Our reputation has attracted talented colleagues from all over the world.
Your development in focus
Working at Wageningen University & Research means being stimulated to meet and extend your boundaries and to further develop yourself within your function and within the organisation.
Expats & new international staff
Moving to a new country is always a challenge. Here, we offer expats and new international staff helpful information for a smooth transition to the Netherlands. You can learn more about coming to Wageningen and practical information about housing, money matters, medical care and more.
WUR Best employer in education
Wageningen University & Research has been declared the best employer in the Education branch in the annual employer survey by Effectory. Martijn...
Despite the restrictive measures due to the corona outbreak, you are still welcome to apply for our job openings. For many positions, the current measures require the application to take place online primarily, and some application processes may take a little longer.
> Check our vacancies
Follow Career at WUR on
All vacancies at WUR
Internationally leading
Active worldwide
Nice colleagues
Working with a functional impairment
Salary, Conditions of employment and collective labour agreement
Educational staff development
Pre-arrival: housing, child care, language
On-arrival: tax, banking, insurance
At destination: health care, buddy system
Career Click to expand
Why choose Wageningen University & Research?

redpajama_set_name: RedPajamaCommonCrawl


The artwork of the product represents a fusion between diverse forms of tribal art. Traditionally, the women of the tribe made auspicious drawings of 'Palghat', the mother goddess with rice paste on walls of the dwellings with bamboo sticks at the time of marriage. The forms are created by joining t..
A traditional Dhokra art piece to be added to your collection of handicrafts. A figure Bell depicting tribal figures that is handcrafted beautifully by craftsmen of eastern India. Dhokra Art is created by using the Lost Wax Process. The name Dhokra is derived from the Dhokra Kumar tribesmen who are ..
This piece of artwork depicts the figurine of a Mother and Child Standing. The woman is shown to attired in her traditional dress, carrying an infant in her hands. The Showpiece is inspired from the pure and wholesome relationship of a mother nurturing her child. This showpiece can be kept as a tabl..
Buy this beautiful palanquin with two palanquin bearers handcrafted in the finest quality of brass by the craftsmen of Dhokra Art. This stunning piece signifies the Indian custom of the Bidai Ceremony after a marriage. This handicraft boasts an impressive detailing that reflects the greatness of thi..
The Dhokra Painting represents a fusion between diverse forms of tribal art. The traditional woman of the tribe made auspicious drawing of their mother goddess 'Palghat' on the walls of the dwellings. The two figures depicted in the product are shown in motion, as if dancing. The use of brass in the..


DDE (p,p-Dichlorodiphenyldichloroethylene) is a white, crystalline solid. It is soluble in water (at 0.010 parts per million), fat, and most organic solvents. It is a degradation product of dichlorodiphenyltrichloroethane (DDT) and is found as an impurity in DDT (HSDB, 1991).


The Exponential Climate Action Roadmap was a major scientific report, published 13 September 2018 at the Global Climate Action Summit in San Francisco. The roadmap outlines the global economic transformation required by 2030 to meet the Paris Agreement on climate, defining clear actionable goals for all sectors of society.
I was responsible for editing together the work of more than a dozen authors into a single, compelling voice, defining the structure, look and feel of the report, and managing all layout and production tasks.
You can download the report free from the Future Earth website.


text:
Q: c++ system() function error  void getresult(char * ip){
char * buf=new char[100];
const char * c=new char[100];
string cmd;
cmd="ping ";
cmd.append(ip);
cmd.append(" >pingresult.txt");
c=cmd.c_str();
system(c);
}

when i run the program in vs2012,there is no problem ,and the process is below
but when i run the ping.exe(my program name) in the Debug f,there's an error "This file is in use by another program, the process cannot access"。 And the process is below
the txt is  called by explore.exe and occupied.

redpajama_set_name: RedPajamaStackExchange


text:
Implementation of ILS CAT-III B at Jaipur and Lucknow Airports road-and-transport-news
New Delhi.Airports Authority of India (AAI) has implemented Instrument Landing System (ILS) – Category-III B at its Jaipur and Lucknow Airports. The implementation of above system at these airports has made them equal to IGI Airport, Delhi in terms of standards of landing facilities for aircraft.
The above work was completed by AAI in less than two years' time with minimum disruption to flights at these major airports. "I am very happy that AAI has been able to complete this complex assignment in two of our busy airports in just 2 years.This will be a major addition to the operational capabilities of AAI's Airport" – said Guruprasad Mohapatra, Chairman of AAI.


text:
Q: How to test for a certain input format I'm trying to test if the next line of input from the standard input has the format:
integer integer integer

with:
while(scanner.hasNext("\\d \\d \\d")){

If this is the format, then I'll read in the integers and do something with them in the while loop.  If the next line is not that format, then I know to do something else, so the loop will break.  However, my code never enters the while loop.  Did I not specify the line format with regex correctly?

A: In all likelyhood, you mean to use the following regex:
while(scanner.hasNext("\\d+ \\d+ \\d+"))

Your regex checks specifically for single-digit numbers.

A: For input such as 1 2 3, the hasNext(String pattern) will only check the first token, i.e. 1, which will not match your pattern.
You can accomplish what you are trying to do in a slightly different way:
Scanner scanner = new Scanner(System.in);
String line;
while ((line = scanner.nextLine()).matches("\\d \\d \\d")) {
    System.out.println("A match!: " + line);
}

@Dolda2000 has a valid point too. Unless you are looking for three single-digit integers only, you want his pattern instead.


text:
Hard Times? Not for iPhone Developers
Author: Brian X. ChenBrian X. Chen
Job seekers struggling to land gigs during the economic downturn are going to wish they had iPhone programming skills.
The demand for iPhone developers worldwide has grown 500 percent in the past six months, according to oDesk, an outsourcing firm for technology jobs.
That translates to an increase from roughly 30 job openings per month to more than 140
positions per month, all seeking app developers, software engineers and other programming and consulting types to build iPhone apps. Those aren't just U.S. companies clamoring for iPhone coders, either: oDesk's network includes employers and job seekers from the United States, Russia, India, Ukraine, China and 100 other countries.
"People are using the iPhone in ways you'd never expect a cell phone to be used," said William Kasel, who posted an ad on Craigslist seeking an iPhone developer for his company BuzzBuy.
"That's why I'm drawn to it."
Kasel is one of many employers catching onto a rumbling mania surrounding the iPhone's popular App
Store. In September – just two months after the App Store's launch – Apple reported that iPhone apps hit a milestone of 100 million downloads. Some independent developers are striking it rich with their iPhone apps. For instance, developer Steve Demeter reported raking in $250,000 in just two months with his popular iPhone game Trism. And even music labels are finding that iPhone apps give them new ways to sell music online.
Some universities are keenly aware of the business opportunities the iPhone has created, and they're readying entire troops of developers by teaching courses on iPhone application development. Stanford was one of the first to offer an iPhone course as part of its computer science program. And more universities will follow, as Apple recently launched iPhone University, giving schools free resources and software to teach iPhone development.
Employers aren't just looking to code apps targeting consumers, either. They're aiming at other businesses, too. BuzzBuy CEO Kasel, for example, is looking for an iPhone developer to code an app that will enable any online store to automatically generate an iPhone app. That way, an iPhone owner could easily browse and make purchases from a web store using its automatically generated app.
A quick browse down the San Francisco Craigslist job board supports oDesk's optimistic view of the iPhone programming market. Almost every other day there's at least one ad demanding an iPhone app developer. The target audiences appear to vary. One ad reads, "So, are you the one? You really have to know your stuff.... Do you like games? Want to help bring one into fruition and build the next killer app for the app store? Ever hear of money? Yeah, we plan on making some of that too."
Sounds quite ambitious, doesn't it?
Maybe – but the demand for developers is driven by continued strong sales of iPhone apps.
Independent coder Shane
Vitarana, who developed the $1 app Drum Kit, said his app is currently selling about 500 downloads a day on average – enough to provide him a steady income. He said he doesn't have exact figures of how much his app has gained him overall, but at one point his app was the 12th most downloaded paid app in the App Store.
Prior to developing for the iPhone, Vitarana was programming Facebook apps – which weren't anywhere near as lucrative.
thought that the iPhone in the App Store was a perfect platform – to make an app and to actually sell it," Vitarana said. "It goes against the whole Web 2.0 model: It seemed more like a traditional model where you could get a product and sell it and get it out to thousands of people with two or three clicks. Plus, it's so easy to buy apps on the iPhone."
Aside from providing Vitarana a steady income, Drum Kit is earning him enough to hire people to help him with future apps. Vitarana currently has a contractor working for him 10 to
20 hours a week, and now he's looking to hire designers.
Makes you want to reconsider your career path if you're not already a coder, right? This could be an opportune time to enroll in a school offering an iPhone development course. Or, you could always pick up a book.
See also:__
Jobs: Apple Is Third Largest Handset Supplier
Stanford Offers iPhone 101: App Developing Workshop
Apple Launches iPhone University Program
iPhone Developers Go From Rags to Riches
Photo: shapeshift/Flickr*


The Magoffin County Fiscal Court met in regular session, discussing flood recovery updates and the possibility of leasing county vehicles to save money. During departmental reports, Magoffin County Judge-Executive Matt Wireman noted that all departments are working hard to get caught up from the February flooding. Emergency management is still gathering data for a possible FEMA declaration and the road department is working non-stop to get to every road with damages.


text:
Interview: Becky Aikman, author of Saturday Night Widows: The Adventures of Six Friends Remaking Their Lives
by Lori M. Myers, Interviews Editor
Author photo by Nina Sabin.
It's said that the only two certainties in life are death and taxes, but I'd like to add one more: good friends who are there when you need them.
Author Becky Aikman would agree. In her book Saturday Night Widows, Aikman redefines "support group" after losing her husband to cancer. She finds five other women who have also experienced loss at an early age and together they look to the future – through laughter and adventure instead of through tears. Aikman's book launches this month in paperback.
Lori: Many of us know the challenges of solitary writing and being happy (or not) with the results, but you had five other people to consider. Did you think about what their feedback might be as you went through the writing process?
Becky: Anyone writing a memoir has to know that it will expose the secrets of lovers, friends, family members, random strangers, just about anyone unlucky enough to cross the writer's path. This was a particular concern with this book, because the five other Saturday Night Widows and I spent so much time together sharing unguarded moments and carrying on conversations that opened up our most intimate thoughts, our most tender misfires, during a time of turmoil and experimentation in our lives. Scary? Yes. Was everyone vulnerable? Yes.
But I knew I had to set that concern aside when I was writing if I wanted to treat the subject honestly. I felt strongly that there weren't realistic books out there about what it's like to start over after a devastating loss. There are quite a few about the raw experience of immediate grief, but not about that next step, when it's necessary to re-imagine a life and face all the choices that have to be made to create a new one.
Luckily, the other Saturday Night Widows felt this as strongly as I did. They gave me carte blanche to write what I wanted, and that included everything from our most private emotions to our faltering attempts at finding love again. The only caveat was that when the manuscript was finished, they could read it and ask me to change their names if they couldn't face the notoriety.
How did they react when you showed them the manuscript?
You can imagine that I spent some nerve-wracking days when it was time for the others to see what I'd done. Luckily, they were unanimous that they wanted readers to read their unvarnished stories, real names and all. I was so grateful. Tara called me and said, "I feel completely naked, but also very brave."
That pretty much sums up what it means to appear in a memoir.
The group you created and the women you gathered far from mirrored what we know as a "support" group for those who are grieving. What was your mindset in creating this group?
The conventional wisdom prescribes a pretty gloomy path for those who have suffered a loss. When it happened to me, people expected me to be sad twenty-four hours a day. They expected me to join a support group that dwelled repeatedly on the trauma of what had happened. As a journalist, I set out to see what research shows about what truly helps people move past grief. In fact, people oscillate between sadness and normality, and those who laugh and smile the most have better well-being in the long run. It also helps to push oneself into new experiences.
So the Saturday Night Widows saw ourselves as a renegade group. When we gathered, it was to share pleasure and adventure. We tried experiences and visited places that were new to us. Did we wind up talking about the many changes we were going through? Definitely. But the idea was that our exploits would open us up to growth and change, and they did.
Congratulations on the book now coming out in paperback. What sort of response have you received from readers? Are you surprised?
There has been a mighty response, which I think shows a hunger in our culture to learn more about how to navigate such a universal event. I've received hundred of letters from readers who were touched by the story or felt it was true to their own lives. Many have formed their own groups. Many have never been widowed but felt it related to other situations in which life takes a sudden turn. I love reading the letters. They say things like, "I laughed and cried, laughed and cried, rinse and repeat." Or: "I am a Saturday Night Widow."
Am I surprised by the reaction? Yes, in part. This is my first book, and I know that it's rare for any book to catch fire. But part of me is not surprised, because I wrote the story I wished I could have read myself, and I suspected there might be others out there who felt the same way.
You and the Blossoms, as the group was named, experienced some wonderful activities and trips together. Which ones were most memorable for you? Which ones do you still participate in?
Most memorable was probably our camel caravan into the Sahara in Morocco. Our goal was to visit a place unlike any we'd seen before, and this strange, spectacular landscape and alien culture fit the bill. The trip helped introduce us to new ways of thinking and feeling. We also loved our tour of the Metropolitan Museum, where engaging with art that reflected on loss and reinvention brought us greater understanding of where we stood in the vast scheme of things.
We still participate in talking and talking and laughing until our insides hurt every time we get together. Oh, and we still like to whip up the molten-center chocolate cookies we learned to make in a cooking class.
[boxer set="Lori-Myers"]
Tags:lori m. myers
← Happy Holidays from Hippo: A Round-up of Seasonal Stories
I Am Here by Nancy Devine →


text:
Supreme Court orders transfer of NRC state coordinator to Madhya Pradesh
Samanwaya Rautray
, ET Bureau Last Updated: Oct 19, 2019, 07:56 AM IST
Supreme Court bench headed by Chief Justice Ranjan Gogoi on Friday ordered inter-cadre transfer of NRC state coordinator Prateek Hajela to Madhya Pradesh on deputation and directed the government to notify his transfer within seven days.
SC transfers NRC Coordinator Prateek Hajela to Madhya Pradesh
NEW DELHI: The Supreme Court on Friday transferred Assam NRC coordinator Prateek Hajela to Madhya Pradesh. A bench led by Chief Justice of India Ranjan Gogoi gave no reasons for the sudden move.
The bench invoked its extraordinary powers to order an inter-cadre transfer of Hajela on deputation to Madhya Pradesh for the "maximum period permissible under the relevant rules/regulations".
"The notification consequent to the above direction will be issued by the competent authority of the Union of India/state government forthwith, and in any case within seven days from today," it said.
The bench will now hear the issue on November 26. The state government, in this case, has been represented by Solicitor General Tushar Mehta and standing counsel Shuvodeep Roy.
The decision took the state government by surprise. Sources said that a lot of work was still left. Those excluded from the National Register of Citizens (NRC) were yet to be given an explanation for it. Appeals against such exclusion can only be filed after this.
This adds to the uncertainty around the controversial exercise. The move to shift out Hajela came amid mounting criticism over the process which has left out over 4 million people in the draft stage alone.
Among those who wrote to the CJI criticising Hajela were former Assam chief minister Tarun Gogoi and MLA Pradip Kumar Bhuyan.
Tarun Gogoi pointed out that there was much resentment against the final NRC in every part of the state. Over 1.9 million people have been excluded from the final NRC, which was unveiled by Hajela on August 31.
"It was expected that the NRC authority would be more cautious and the final NRC would be errorfree, but unfortunately it has been found to be contrary, as lakhs of people belonging to all communities and religion were excluded from the list, which has created a lot of confusion and uncertainty among them," Tarun Gogoi said.
He also accused Hajela of not discharging his duty and responsibility effectively and efficiently, though he had coopted 50,000 staff into the exercise and spent over Rs 1,200 crore.
The NRC list has been rejected by all, he said.
Tarun Gogoi blamed the central government, the implementing authority, for the mess. Referring to the exclusion of former army officers, police officials, MLAs, ex-MLAs and family members of late president Fakhruddin Ali Ahmed, besides thousands of other Indian passport holders from the NRC, he said that if they are Indian citizens, why should they go to the foreigners' tribunals? He also demanded to know the fate of those who had been included in the 2019 voters' list by establishing their link to the 1966 voters list.
( Originally published on Oct 18, 2019 )
In Video: SC transfers NRC Coordinator Prateek Hajela to Madhya Pradesh
Ranjan GogoiSupreme CourtMadhya PradeshNRC


text:
Prospective Investors
2021 ESG Report
Viatris Transaction
Historical Stock Quote
Dividend & Split History
Stock FAQs
Corporate Governance Overview
Board Committees & Charters
Corporate Governance FAQs
Contact Our Directors
Shareholder Services Overview
Pfizer Investor Insights
Cost Basis Calculator
Supplemental Annual Meeting Q&A
Guide to Clinical Trials
Your participation makes a difference
Clinical Trials in Children
Designed to improve kids' health
Data and Results
Sharing our Results
Integrity and Transparency
Equity and Representation
Plain Language Study Results
Trial Result Summaries
Expanded Access & Compassionate Use
Possible Treatment Options
Smaller populations but big impact
Extending lifespans worldwide
Inflammation & Immunology
Treatment at the molecular level
Preventing the spread of infections
The science of optimism
Anti Infectives
Combatting an evolving risk
Breakthroughs become treatments
Medicinal Sciences
The next generation of science
Developing tailored medicines
Maternal Immunization
Protecting newborns at the start
Unleashing the next wave of scientific innovations
Branded vs. Generic
Learn the difference
Biologics & Biosimilars
Cures found in nature
Maintaining the highest standards
Global Supply
Strategic manufacturing locations
Manufacturing Sites
Where medicine is made in the U.S.
Learning to be well
Treatment Choices
Learning about treatment decisions
Partnering with Patients
Helping others by reporting side effects
Tips for Patients
Preventing medication errors
Online Counterfeit Medicines
Combating the Rise
When AI Meets Biology
A Special Partnership
What is mRNA?
mRNA Defined and Applied
COVID-19 Vaccine Rollout
New Digital Technologies
Distributing Hope to the World
Where Science Meets Patients
The Art of Creating New Medicines
Update & Statements
Our senior-most leadership
The people steering our company
Our experts making discoveries
Each of us is responsible
Everyone has something to offer
Our responsibility to the environment
Meeting urgent needs worldwide
Furthering dignity and worth
The benefits of fair competition
Patient Advocacy & Engagement
Putting Patients First
Support for independent research
Political Partnership
Supporting like-minded organizations
Working with Healthcare Professionals
Collaboration to improve lives
Prescription Value & Pricing
How to lower patient costs
Ready for Cures
Improving Access to Medicines
Transparency in Grants
Committed to Disclosure
Information for stockholders
Why to join us on our mission
Quarterly reports and more
Announcements about our performance
Charts and data
Information on stock transactions
Gaining insight into our performance
Defining the corporate structure
The Pfizer Board Policies
Ensuring ethical leadership
Learn more about our approach
Email any of our Directors
Current Location and Language
- Español
- Deutsch
- Belarusian - English
- English - Nederlands - Français
- Português
- Български
- English - Français
- 中文 - English
- Croatian
- Čeština
- Dansk
- Eesti - English
- Suomalainen
- ελληνικά
- 繁體中文 - English
- Magyar
- עברית
- Italiano
- 日本の
- 한국의
- Latvian - English
- Lithuanian - English
- Norsk
- Polski
- Русский
- Română
- Serbian
- English - العربية
- Slovenian
- Slovenský
- Svenska
- Deutsch - Français
- Taiwan
- ภาษาไทย
- Türk
- Ukrainian
- Tiếng Việt - English
Overview > Investor Relations > News > News Details
U.S. FDA Accepts for Review the Biologics License Application for Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
Download(opens in new window)PDF
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY for the prevention of meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age.
The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA on the pentavalent meningococcal vaccine application is in October 2023.
Pfizer's MenABCWY vaccine candidate combines the components of two vaccines into one, helping protect against the meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.1 In the U.S., approximately 55 million adolescents and young adults are in the age range for meningococcal vaccination (11-23 years old), according to ACIP recommendations.2
"The FDA's acceptance of our application for the pentavalent meningococcal vaccine candidate is an essential step toward helping protect individuals and communities against the most common types of meningococcal disease," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. "We believe our investigational MenABCWY vaccine, if approved and recommended, could help simplify the meningococcal vaccination schedule for adolescents and young adults, and in turn improve vaccination rates, and provide the broadest serogroup coverage of any meningococcal vaccine. The pentavalent vaccine candidate was well-tolerated in clinical trials, with a safety profile consistent with currently licensed meningococcal vaccines."
The regulatory submission is supported by previously announced positive results from a randomized, active-controlled and observer-blinded Phase 3 trial assessing the safety, tolerability, and immunogenicity of the pentavalent vaccine candidate compared to currently licensed meningococcal vaccines, with the goal of determining immunologic noninferiority. The Phase 3 trial (NCT04440163) evaluated more than 2,400 patients from the U.S. and Europe.
Potential U.S. Public Health Impact of a MenABCWY Vaccine
Meningococcal disease is an uncommon but serious illness that can lead to death within 24 hours and, for survivors, can result in life-altering, significant long-term disabilities.3 Together, the five most common meningococcal serogroups account for 95 percent of all IMD cases worldwide, with serogroup B accounting for the majority of disease in adolescents and young adults in the U.S. and Europe.1
In the U.S., the current meningococcal vaccination platform for adolescents and young adults includes a routine recommendation for MenACWY vaccines (two doses) and a separate, shared clinical decision recommendation for MenB-specific vaccines (two doses) in order to achieve the broadest serogroup protection available against meningococcal disease. However, less than a third of U.S. adolescents receive even one dose of a MenB vaccine, and fewer complete the series.4,5 If approved and recommended, Pfizer's pentavalent vaccine candidate could be another option for the current routine recommendations in place for MenACWY vaccines. Pfizer's pentavalent vaccine candidate could potentially reduce the total number of doses needed for individuals to be fully vaccinated against the five serogroups, thereby simplifying meningococcal vaccination and increasing the number of adolescents and young adults vaccinated.6 Routine use of a MenABCWY vaccine could reduce IMD cases and associated mortality, the rate of long-term sequelae in survivors, and costs associated with controlling outbreaks.7
About the Pentavalent Meningococcal Vaccine Candidate (MenABCWY)
Pfizer's pentavalent meningococcal vaccine candidate combines the components from its two licensed meningococcal vaccines, Trumenba® (meningococcal group B vaccine) and Nimenrix® (meningococcal groups A, C, W-135, and Y conjugate vaccine); approvals of Nimenrix® and Trumenba® vary by country. Together, the 5 serogroups included in MenABCWY are responsible for the majority of currently circulating meningococcal disease globally.1 Top line results from a randomized, active-controlled and observer-blinded Phase 3 trial of Pfizer's pentavalent meningococcal vaccine candidate (NCT04440163) were previously announced in September 2022. Additional information about the trial and results can be found at www.clinicaltrials.gov.
INDICATIONS FOR TRUMENBA® IN THE U.S.
Trumenba® is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
Trumenba® should not be given to anyone with a history of a severe allergic reaction to any component of Trumenba®
Some individuals with weakened immune systems may have a reduced immune response
Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba®
Vaccination with Trumenba® may not protect all vaccine recipients against N meningitidis group B infections
Fainting can occur in association with administration of injectable vaccines, including Trumenba®
The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain
Data are not available on the safety and effectiveness of using Trumenba® and other meningococcal group B vaccines interchangeably to complete the vaccination series
Tell your health care provider if you are pregnant, or plan to become pregnant
Ask your health care provider about the risks and benefits of Trumenba®. Only a health care provider can decide if Trumenba® is right for you or your child
INDICATION FOR NIMENRIX® IN THE E.U.
Nimenrix® is a vaccine indicated for individuals six weeks of age and older for active immunization to prevent invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y
Nimenrix® should not be given to anyone with a history of a severe allergic reaction after a previous dose of Nimenrix®
Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W, and Y, even with receipt of vaccination with Nimenrix®
As with any vaccine, vaccination with Nimenrix® may not protect all vaccine recipients against N. meningitidis groups A, C, W and Y
Fainting can occur shortly before or after injecting vaccines, including Nimenrix®
The most common adverse reactions were loss of appetite, irritability, drowsiness, headache, fatigue, fever, and pain, redness, and swelling at the injection site
Tell your healthcare provider if you are pregnant, or plan to become pregnant
Ask your healthcare provider about the risks and benefits of Nimenrix®. Only a healthcare provider can decide if Nimenrix® is right for you or your child
Menveo® and Nimenrix® are trademarks of GlaxoSmithKline Biologicals S.A.
Soliris® is a trademark of Alexion Pharmaceuticals, Inc.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
The information contained in this release is as of December 28, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer's MenABCWY vaccine candidate, including its potential benefits, a BLA pending with the FDA and its potential recommendation, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any biologic license applications may be filed in particular jurisdictions for Pfizer's MenABCWY vaccine candidate; whether and when the BLA pending with the FDA or any such other applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether such product candidate will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer's MenABCWY vaccine candidate; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities for Pfizer's MenABCWY vaccine candidate and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
1 National Library of Medicine. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. September 2019. Available at: https://doi.org/10.1016/j.micpath.2019.103571. Accessed June 2, 2022.
2 Centers for Disease Control and Prevention. Meningococcal vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. September 2020. Available at: https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm. Accessed December 19, 2022.
3 Borg J, Christie D, Coen PG, Pooy R, Viner RM. Outcomes of Meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123:e502-e509. Available at: https://pubmed.ncbi.nlm.nih.gov/19254985/. Accessed December 19, 2022.
4 Pingali C et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2021. Available at: https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7135a1-H.pdf. Accessed November 17, 2022.
5 La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021;39(19):2660-2667.Available at: https://pubmed.ncbi.nlm.nih.gov/33849722/. Accessed December 19, 2022.
6 National Library of Medicine. Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review. 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/35357651/. Accessed December 19, 2022.
7 National Library of Medicine. Potential Public Health Impact of a Neisseria Meningitidis A, B, C, W, and Y Pentavalent Vaccine in the United States. 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/33615973/. Accessed December 19, 2022. https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htmhttps://pubmed.ncbi.nlm.nih.gov/19254985/
Category: Vaccines
Media Contact: +1 (212) 733-1226
PfizerMediaRelations@Pfizer.com
Investor Contact: +1 (212) 733-4848
IR@Pfizer.com
Source: Pfizer Inc.
Multimedia Files:
At Pfizer, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. If you experience any issues with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to Pfizer to send you the requested Investor Email Alert updates.
United States © Pfizer Inc. All rights reserved
Forward-Looking Statements of Pfizer Inc.
This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; manufacturing and product supply; our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitor; our expectations regarding the impact of COVID-19 on our business; plans for and prospects of our acquisitions, dispositions and other business-development activities, and our ability to successfully capitalize on these opportunities; and discussions relating to strategic reviews, capital allocation objectives, dividends and share repurchases, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
A description of these risks and uncertainties can be found in Pfizer's most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the transcript speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.
This webcast may contain forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitor; and our expectations regarding the impact of COVID-19 on our business that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
`; var globeIcon = ' '; $('#navDesktopSearch').append(contactUs); $('#navDesktopSearch').append(globeIcon); //breadcrumbs $('.module-breadcrumb .module_container--inner a:nth-of-type(2)').attr('href', '/Investors/Overview'); $('.module-breadcrumb .module_container--inner a').each(function() { if ($(this).html() == 'Financials') { $(this).hide(); $(this).next().hide(); } }); $('.nav--desktop > ul > li:last-of-type > a').addClass('active');


text:
Q: Python Pandas: regroup data horizontally for every fifteen-minutes-range I am very new to Python for data analysis and my task is to re-organize an auto-generated csv-file, in which four companies are monitored in their energy-consume (in megawatt) for the whole month of July 2022.
The energy-consume is reported for the companies every 15 minutes from July 1 (00:15) until July 31 (23:45). This is how the original dataframe looks like:

Index
Date
Quarter
Company
Mw

1
01.07.2022
00:15
Company A
0

2
01.07.2022
00:15
Company B
0

3
01.07.2022
00:15
Company C
10

4
01.07.2022
00:15
Company D
15

1
01.07.2022
00:30
Company A
0

2
01.07.2022
00:30
Company B
0

3
01.07.2022
00:30
Company C
1

4
01.07.2022
00:30
Company D
150

1
01.07.2022
00:45
Company A
-130

2
01.07.2022
00:45
Company B
120

3
01.07.2022
00:45
Company C
110

4
01.07.2022
00:45
Company D
0

...

1
02.07.2022
00:15
Company A
0

2
02.07.2022
00:15
Company B
0

3
02.07.2022
00:15
Company C
160

4
02.07.2022
00:15
Company D
180

1
02.07.2022
00:30
Company A
10

2
02.07.2022
00:30
Company B
0

3
02.07.2022
00:30
Company C
-145

4
02.07.2022
00:30
Company D
150

1
02.07.2022
00:45
Company A
-180

2
02.07.2022
00:45
Company B
115

3
02.07.2022
00:45
Company C
145

4
02.07.2022
00:45
Company D
0

...

This is how the new data frame should look like. All the megawatt-values should be reported horizontally for every fifteen-minutes-range until the end of July grouped by Date and Company:

Date
Company
00:00-00:15
00:15-00:30
00:30-00:45
…

01.07.2022
Company A
0
0
-130

01.07.2022
Company B
0
0
120

01.07.2022
Company C
10
1
110

01.07.2022
Company D
15
150
0

…

02.07.2022
Company A
0
10
-180

02.07.2022
Company B
0
0
115

02.07.2022
Company C
160
-145
145

02.07.2022
Company D
180
150
0

…

Since I have never programmed with Python before, I am very confused on how would be the best way to reach this task. I am not asking you to give me the whole solution, just a hint on which would be the best methods from Pandas (stack/unstack, pivot). Thank you very much in advance.

A: I applied a pivot_table to the dataframe, where the indices are 'Company', 'Date', values 'Mw'. Columns are created from 'Quarter' rows. In the received data, indexes are reset using reset_index().
The data looks like this:
Quarter        Date    Company  00:15  00:30  00:45
0        01.07.2022  Company A      0      0   -130
1        01.07.2022  Company B      0      0    120
2        01.07.2022  Company C     10      1    110
3        01.07.2022  Company D     15    150      0
4        02.07.2022  Company A      0     10   -180
5        02.07.2022  Company B      0      0    115
6        02.07.2022  Company C    160   -145    145
7        02.07.2022  Company D    180    150      0

To order them as in your example sort_values(by='Date') is used.
Delete the index name:
df1.rename_axis(None, axis=1, inplace=True)

Indexes are set from 0 to n.
Next, in the list generator, the names of the required columns are created and they are renamed.
All together:
import pandas as pd
import numpy as np

df = pd.read_csv('df2.csv', header=0)

df1 = df.pivot_table(index=['Date', 'Company'], columns='Quarter', values='Mw')

df1 = df1.reset_index().sort_values(by='Date')
df1.rename_axis(None, axis=1, inplace=True)
df1 = df1.set_index(np.arange(0, len(df1)))

hist = len(df1.columns)
arr = ['00:00' + '-' + str(df1.columns[2])]
[arr.append(df1.columns[i - 1] + '-' + df1.columns[i]) for i in range(3, hist)]
df1.columns.values[2:] = arr#Renaming columns
print(df1)

Output
         Date    Company  00:00-00:15  00:15-00:30  00:30-00:45
0  01.07.2022  Company A            0            0         -130
1  01.07.2022  Company B            0            0          120
2  01.07.2022  Company C           10            1          110
3  01.07.2022  Company D           15          150            0
4  02.07.2022  Company A            0           10         -180
5  02.07.2022  Company B            0            0          115
6  02.07.2022  Company C          160         -145          145
7  02.07.2022  Company D          180          150            0


With him came one of Hts people and Mrz-i-mal-i-qrlqs son Shh asan.
When Hts kinsman was given leave to go he took for Ht a sword and head-to-foot (bsh-ayq) with a royal letter of encouragement.
Al Jang-jang, came to the bank of the river with Hts offering of an accoutred horse.
Dost Beg led his reserve forward, made a strong attack, dismounted a number of Hts men, and beat him.


text:
Rudolf "Rudi" Dassler (Herzogenaurach, Baviera, Alemania, 26 de marzo de 1898 - 27 de octubre de 1974, Ibídem, Alemania) fue un empresario alemán. Fundador de la compañía de ropa deportiva Puma y el hermano mayor del fundador de Adidas, Adolf "Adi" Dassler.

Los hermanos eran socios en una empresa de zapatos que fundaron ambos en 1924, Gebrüder Dassler Schuhfabrik (Fabrica de Zapatos de los Hermanos Dassler). Después de la Segunda Guerra Mundial, en 1948, se separaron y cada uno fundó su propia empresa. Rudolf denominó a su empresa como "Ruda" (Rudolf Dassler) pero posteriormente cambió el nombre al que continúa siendo actualmente: PUMA.

Bajo su dirección PUMA fue una empresa pequeña, provincial. Sólo bajo la dirección de su hijo Armin Dassler PUMA llegó a ser la empresa mundialmente conocida que es hoy.

Rudolf Dassler murió el 27 de octubre de 1974 de cáncer de pulmón.

Enlaces externos
Puma Website.

Empresarios de Alemania
Puma (marca)

redpajama_set_name: RedPajamaWikipedia


text:
/*
 *  Altair Admin angularjs
 *  controller
 */

angular
    .module('agooDash')
    .controller('mainCtrl', [
        function () {}
    ])
;

redpajama_set_name: RedPajamaGithub


U2 continues with the chorus: "In the name of love / What more in the name of love." They repeat these words over and over again, astonished and overwhelmed by the lengths to which love calls us to go. From 1984's The Unforgettable Fire, the song bears the title "Pride (In the Name of Love)" and easily slots into my Top 10 list of all-time favorite U2 songs. It's one of those songs that I never skip when those first rifts from The Edge's guitar bloom on my radio.


text:
Order a Brochure Find a Store
Flight Centre UK
All Holiday Types
Long-Haul
What are Tailor-made Holidays?
ALL FLIGHT TYPES
Multi-Stop Flights
Round the World Flight Upgrades
All Flights
Premium Cabin Flights
Premium Airlines
Flights from the UK
Call FREE: Mon-Fri: 9am-7pm, Sat-Sun: 9am-6pm
Many of our deals are not available on our website. For regional departures, different travel dates or a quote on a specific airline or hotel please call our experts who will find the right deal for you at the best price.
Our opening hours are Mon-Fri: 9am-7pm, Sat-Sun: 9am-6pm.
Call free on landline:
Call free on mobile:
I'm happy just browsing
6 of the Best Lord of the Rings Locations in New Zealand
In 2019, it's 64 years since The Return of the King – the third and final instalment in JRR Tolkien's world-famous fantasy trilogy – first hit the bookshelves. Beloved wizard Gandalf the Grey once said: "All we have to decide is what to do with the time that is given us." And to mark this momentous literary milestone, all we want to do with our time is see the Lord of the Rings in real life. Enter New Zealand.
Here are six must-visit locations in the Land of the Long White Cloud or, as us Tolkien nuts know it, Middle Earth…
RS-Matamata-Hobbiton-NZ-shutterstock_274005014.jpg
Otherwise known as: Hobbiton
Just two hours south of Auckland, Rotorua is home to acres upon acres of Waikato farmland – aka Matamata, aka Hobbiton, in all its glory. Visitors can take a tour of this verdant, scenic region and explore cluttered Hobbit holes (including the delights of Bag End), have a pint at the Green Dragon Inn and discover the abundant buildings and structures that make up The Shire. It's a necessity for fans of the franchise, not to mention nature lovers: think rolling green hills, emerald hedgerows and sheep by the field-load.
RS-Mt-Nguaruhoe-Tongariro-NP-NZ-shutterstock_102136414.jpg
Otherwise known as: Mordor and Hidden Bay, the entrance to The Lonely Mountain in The Hobbit: The Desolation of Smaug.
Tongariro National Park is home to the Dark Lord Sauron and his crimson, all-seeing eye. Tolkien aficionados will recognise the lava-clad Mount Ngauruhoe – an active stratovolcano in the heart of the park – as the infamous Mount Doom, although in reality it's often topped with white powder rather than spewing red-hot magma. That doesn't stop keen hikers from trekking to the summit and throwing their rings in to save Middle Earth though. What better activity for wannabe heroes/hobbits?
RS-New-Zealand-Wellington-City.jpg
Otherwise known as: Lord of the Rings – behind the scenes
Wellington is where the real movie magic happens. All the stuff behind the scenes – from SFX to post-production and editing – is done in Wellington. In fact, both The Lord of the Rings and The Hobbit trilogies (as well as a long list of other blockbusters) were finished up here and it's where most of the cast, including the wondrous Elijah Wood, spent a lot of their shooting time.
This movie hub is also home to the Weta Cave in Miramar, a tour-worthy museum boasting original movie props, memorabilia and artwork. Any discerning fantasy film fanatic will feel like they've died and gone to heaven here.
RS-Lake-Pukaki-Queenstown-NZ-shutterstock_186693569.jpg
Otherwise known as: Lake-Town, the Pillars of the King
Queenstown is full of postcard-perfect scenes, no more so than those at Lake Pukaki – a surreal turquoise lagoon where the Hobbit-famous Lake-Town was shot. This glacier-fed inlet is just as mesmerising in reality as it is in the films, even more so in fact, as the waters are undisturbed by dragon fire. Instead they are flanked by the snow-capped peaks of the Southern Alps and, dependant on the season, surrounded by emerald or golden-brown trees. It's an almost ethereal place, and it's easy to see why Peter Jackson fell in love with it.
RS-Te-Anau-NZ-shutterstock_261473084.jpg
Te Anau & Milford Sound
Otherwise known as: Fangorn Forest
One glance at the pretty lakeside town of Te Anau and its backdrop – the iconic Milford Sound – and it's easy to see why it was one of Jackson's favourite shooting locations. Everything from the intensity of the soaring mountains, to the drama of the thunderous waterfalls, to the call of the wild in the lush forests, played a huge part in the trilogy, especially The Two Towers.
Remember the Great River Anduin? Or the Dead Marshes, where Frodo was rescued by Gollum? How about Fangorn Forest? The latter is perhaps the region's most famous Lord of the Rings link; a mystical, deep, dark woodland that sits in the shadow of the Misty Mountains. In reality it's not Hobbits bearing rings that roam here though; intrepid travellers and backpackers love to explore this rugged yet beautiful enclave on the west coast of the South Island.
RS-Kaitoke-Regional-Park-NZ-shutterstock_166229756.jpg
Kaitoke Regional Park
Otherwise known as: Rivendell
It doesn't get more Lord of the Rings than Rivendell. And it doesn't get much more mystical than Rivendell's body double – the Kaitoke Regional Park – either. It's wilderness at its most wild, ripe for tramping, camping, horse riding and bike rides along bush-clad trails, yet it still maintains an air of tranquillity. It's no wonder Jackson saw it as the perfect Elvish spot. Most of Rivendell was made-up of CGI of course, but look hard enough and your imagination will see the Tolkien in the towering trees, calm river pools and cliff-side greenery.
Want to discover New Zealand, Hobbiton and the rest of the LOTR-verse for yourself? Speak to one of our Travel Experts about our Middle Earth Explorer Journey. Call 0800 587 0058 or visit us in-store.
6 Things to Know Before Campervanning around New Zealand
New Zealand's Secret Islands
Alexandra Cronin (Gregg)
Once a roving local news reporter and now a travel-obsessed writer/sub, I'm head-over-heels for nature, wildlife and the ocean. When I'm not getting up close to animals and sea creatures, I'm seeking out the sets of my favourite TV shows around the world. Follow me @wonderg1rl89.
First and Business Class
Quirky Travel
The Travel Team
Talk to a Travel Expert
Instant call back »We'll call you back for free
We'll call you back shortly
Please enter a valid UK landline or mobile number
Get a quote » A consultant will contact you
Visit a store »Plan ahead and request an appointment
First and Business
All Tailor-Made Holidays
About Flight Centre
Trust & Compliance
Be the first one to get our deals
We'd love to send you our latest holiday offers and travel inspiration by email. To sign up, please enter your details below.
We're passionate about travel and want to inspire you, however, you have the right to withdraw your consent from marketing communications at any time.
We value our customers' privacy and will treat your personal details with the utmost care and respect. For information about how we handle your data, please read our Privacy Policy.
© 2019 Flight Centre (UK) Limited, Registered in England No. 02937210
* 0800 calls are free for landlines and mobiles. 0333 calls are included within inclusive minutes package on mobiles, otherwise standard rates apply.
0844/0845 calls are 7p/pm plus your local carrier charge.
Speak to one of our lovely humans
Put you number below to request a call back
Instant call backWe'll call you back for free
Get a quote A consultant will contact you
Visit a storeRequest an in store appointment


text:
Q: Friis transmission equation: antenna gains I'm trying to determin the distance ,with the Friis equation :

where G t and G r are the antenna gains. I would like to know how to determine  the Gt and the Gr in general ?I'm using Wi-Fi. And in my case the transmitter is the Access point and the receiver is an android mobile, how can i know them ,are the Gt and the Gr constants ?
PS: I'm working in free space.
Thank you in advance.

A: Usually for a simple router, the antenna is a dipole so its gain would be 1.65 or 2.15dBi. In case of the cell phone the antenna gain would be similar to the dipole or lower. It can be simply taken as 1 or 0dBi.


FOLLOW MYSTIC POST ON FACEBOOK!
Jesus speaks of the power of blessing to mystically stigmatized German Teresa Neumann Dear daughter, I want to teach you to receive My Blessing with fervor. Try to understand that something great happens when you receive the blessing from one of my priests.
The blessing is an overflow of my Divine Holiness. Open your soul and let it become holy through my blessing. It is celestial dew for the soul, through which everything that is done can be fruitful. Through the power of blessing, I gave the priest the power to open the treasure of My Heart and to pour a shower of graces on souls.
When the priest blesses, I bless.
Then an endless stream of graces flows from My Heart to the soul until it is completely filled. In conclusion, keep your heart open so as not to lose the benefit of blessing. Through my blessing you receive the grace of love and help for the soul and the body. My Holy Blessing contains all the help that is needed for humanity.
Through it you are given the strength and desire to seek good, to escape evil, to enjoy the protection of My children against the powers of darkness. It is a great privilege when you are allowed to receive the blessing. You can not understand how much mercy comes to you through him.
Therefore never receive blessing in a flat or distracted way, but with all your complete attention !! You are poor before receiving the blessing, you are rich after receiving it.
It grieves me that the blessing of the Church is so little appreciated and so rarely received. Good will is strengthened by its means, initiatives receive my particular Providence, weakness is strengthened by my Power.
Thoughts and intentions are spiritualized and all bad influences neutralized. I gave my Blessing powers without boundaries: it comes from the Infinite Love of my Sacred Heart. The greater the zeal with which the blessing is given and received, the greater is its effectiveness.Whether a child is blessed, or the whole world blessed, the blessing is far greater than 1000 worlds.
Reflect that God is immense, infinitely immense.
How small things in your comparison! And it happens the same, whether only one, or that many receive the blessing: this does not matter because I give to each one according to the measure of his faith! And since I am infinitely rich in all goods, you are allowed to receive without measure.
Your hopes are never too big, everything will exceed your deepest expectations! My daughter, protect who gives you the blessing! Highly esteem the blessed things, so you will like Me, your God. Whenever you are blessed, you are closer to Me, sanctified again, healed and protected by the Love of my Sacred Heart.
Often I keep the results of my Blessing hidden so that they are known only in eternity. It often seems that the blessings have not resulted, but their influence is marvelous; even the apparently unsuccessful results are a blessing obtained through Holy Blessing; these are the mysteries of my Providence which I do not wish to manifest.
My Blessings often produce effects unknown to the soul. Therefore, have great confidence in this overflowing of My Sacred Heart and seriously reflect on this favor (what the apparent results are hidden from you).


text:
You are viewing archived content
of the Inter-American Foundation website as it appeared on June 1, 2018.
Content in this archive site is NOT UPDATED.
Links and dynamic content may not function, and downloads may not be available.
External links to other Internet sites should not be construed as an endorsement of the views contained therein.
Go to the current iaf.gov website
for up-to-date information about community-led development in Latin America and the Caribbean.
Español Kreyol Português FAQ Contact Us Newsletter
About the IAF
More about the IAF
Board & Advisory Council
Reporting and Accountability
IAF Jobs
Grantee Perception Report
Grassroots Development Journal
Board of Directors and Advisory Council
Caribbean (Regional)
Latin American (Regional)
New Directions in Funding
Applying for an IAF Grant
Results Reports
From our Grantee Partners
Resources » Publications » Annual Reports » 2002
Asociación Unidad por el Desarrollo Comunitario (UDECO), $296,236, over three years, to train 1,200 people from 200 families in new forms of community organization and production technologies and to improve food security and family income through a loan fund for agricultural, forestry and livestock development. (NC-240)
Asociación de Consultores para el Desarrollo de la Pequeña, Mediana y Microempresa (ACODEP), $395,300, over three years, to develop an integrated housing program for 3,200 low-income families. Poor households will receive technical assistance and training in design and construction as well as financial services for home improvements or new housing. (NC-243)
Fondo de Desarrollo para la Mujer-Cenzontle (FODEM), $472,727 for a three-year credit and training project contributing to the economic development and empowerment of 9,600 low-income women micro-entrepreneurs. (NC-244)
Movimiento por la Paz, Acción Forestal y el Medio Ambiente (MOPAF-MA), $356,883, over three years, to organize, train and strengthen territorial networks of farmers working to recover an area of approximately 360 square kilometers. The award to MOPAF-MA will benefit approximately 1,500 families in eight communities, especially those residing on the lower hillside and slopes of the watershed basin of Lake Managua. (NC-247)
Asociación para el Desarrollo Económico con Equidad (Alternativa), $271,400, over three years, for a program directed at developing and strengthening, through technical assistance and access to credit, approximately 1,200 micro-and small enterprises involved in production, service and commercial activities in urban and rural areas in the municipality of Masaya. (NC-248)
Cooperativa Agropecuaria de Servicios de Extracción de Aceites Esenciales, R.L., El Bálsamo (COOPE- SIUNA), $162,500 to configure, install, maintain and operate a business owned by allspice producers residing in the buffer zone of the BOSAWAS Biosphere Reserve. COOPESIUNA members will use renewable energy technologies (solar and biofuel) to produce and market ground allspice and allspice essential oil. (NC-249)
Cooperativa de Servicios Múltiples San Isidro R. L. (COOPECAFÉ), $122,000 to configure, set up, operate and maintain an enterprise that will use a solar/biomass drying system to process coffee for sale locally and internationally, benefiting approximately 1,200 people associated with 200 small- and medium-scale coffee producers. (NC-250)
Supplemental Grants over $10,000
Fundación por la Unidad y Reconstrucción de la Costa Atlántica (FURCA), $50,780 for purchasing replacement vegetable and fruit seeds, plants, tree seedlings, and small animals. The amendment will also support training and technical assistance for project beneficiaries and FURCA's additional administrative and operational expenses. (NC-232-A1)
Capturing Value Added for Farmers' Cooperatives
By Miriam Brandão, Senior Foundation Representative for Central America
The Cooperativa Agropecuaria de Servicios de Extracción de Aceites Esenciales R.L, El Bálsamo (COOPESIUNA) and the Cooperativa de Servicios Múltiples San Isidro R.L. (COOPECAFÉ) were formed with the help of the Programa de Campesino a Campesino (PCAC), sponsored by the Nicaraguan NGO Union Nacional de Agricultores y Ganaderos, which has offered farmers in Nicaragua "horizontal" technical assistance and training for more than 15 years. IAF's goal in supporting these two rural cooperatives is to assist their development into agro-industries that use sustainable methods to capture value added from processing and direct export.
COOPESIUNA, which obtained its legal status in 1999, operates in the buffer zone of the BOSAWAS Biosphere Reserve. Its members have launched an enterprise using renewable energy technology (solar and biofuel) to cultivate indigenous allspice, harvest the berries and leaves, and extract their highly valued essential oils. The farmers have established nurseries for thousands of allspice trees as well as citrus trees, cocoa and other appropriate forest cover species. COOPESIUNA aims to significantly increase revenue for member families and to introduce sustainable extraction methods to preserve the forest ecosystem and associated biodiversity.
With $162,500 from the IAF, COOPESIUNA will develop and implement a capacity-building, training and marketing program to support the installation, operation, maintenance and repair of solar and related equipment. It will assist in the design and configuration of the processing plant and the operational plan for the cooperative and provide quality control and support for processing and export activities. Members will receive training in mixed-use agroforestry, nursery, and planting and harvesting techniques. Initially, the project will benefit the 69 members of the cooperative and their families, approximately 400 people. Another 250 families involved in allspice production in the zone will benefit from the project's future expansion.
COOPECAFÉ, incorporated in 2000, belongs to 200 small- and medium-scale coffee producers residing in six municipalities in the department of Boaco. The cooperative purchased land and, with a grant from the Austrian development agency, constructed a facility that allows coffee growers to process their own harvest using an off-grid, stand-alone solar/biomass coffee mill, as well as stores and helps export coffee for COOPECAFÉ members. IAF's award of $122,000 will co-finance a drying system and milling and sorting equipment. It will also provide the remaining investment capital needed to make the farmer-owned coffee mill operational as well as working capital and equipment for a roasting company owned and operated by women of the cooperative. In all, the project will benefit 1,400 people, including COOPECAFÉ's members and their families.
COOPESIUNA and COOPECAFÉ also receive support from the Mesoamerican Development Institute, the World Bank's Global Environment Facility, the Frontera Agrícola Program of Nicaragua's Ministry of Natural Resources and the Environment, and Oxfam-United Kingdom. In three years, their members should be fully trained in all phases of the processing equipment and able to manage their enterprises without outside assistance. Their members' income should increase substantially through processing, marketing and the direct export of biodiversity-friendly coffee and essential allspice oil. Finally, it is anticipated that these projects will result in decreased destruction of native forests through conventional farming practices.
FOIA Legal Notices Privacy Policy No Fear Act Open Government Site Map
202.360.4530 Inter-American Foundation 1331 Pennsylvania Ave. NW
Suite 1200 North
© 2018 Inter-American Foundation. All Rights Reserved. | Website Created & Hosted by Vision Internet – Innovators of Online Government


text:
Franklinia
(Redirected from Franklinia alatamaha)
Flower and leaves in autumn
Extinct in the Wild (IUCN 3.1)[1]
Clade: Angiosperms
Clade: Eudicots
Clade: Asterids
Family: Theaceae
Genus: Franklinia
W.Bartram ex Marshall[2]
F. alatamaha
Franklinia alatamaha
Natural range
Franklinia alatama Raf.
Gordonia franklinii L'Hér.
Gordonia pubescens L'Hér.
Franklinia is a monotypic genus in the tea plant family, Theaceae. The sole species in this genus is a flowering tree, Franklinia alatamaha, commonly called the Franklin tree, and native to the Altamaha River valley in Georgia in the southeastern United States. It has been extinct in the wild since the early 19th century, but survives as a cultivated ornamental tree.
In the past, some botanists have included Franklinia within the related genus Gordonia. The southeastern North American species Gordonia lasianthus differs in having evergreen foliage, flowers with longer stems, winged seeds, and conical seed capsules. (Franklinia was often known as Gordonia pubescens until the middle of the 20th century.)
Franklinia is now thought to be closer in relation to the Asian genus Schima. Recent DNA studies and examinations of floral ontogeny in the Theaceae place Franklinia together with Gordonia and Schima in a subtribe.[3] Hybrid crosses have been produced between Franklinia alatamaha and Gordonia lasianthus, and between Franklinia alatamaha and Schima argentea.[4][5]
Franklinia alatamaha is a deciduous large shrub or small tree growing to 10 m (33 ft) tall, but commonly 4.5–7.5 m (15–25 ft). It is commercially available for garden cultivation. It is prized for its lightly fragrant white flowers, similar to single white Camellia blossoms; the smell may remind some of orange blossoms or honeysuckle. The tree has a symmetrical, somewhat pyramidal shape, often with different individuals of the species forming almost identical crowns. It frequently suckers and can form several vertical trunks close to ground level. The bark is gray with vertical white striations and has a ridged texture. The alternate, obovate leaves are up to 6 in (15 cm) in length and turn a bright orange-red in the fall. Although difficult to transplant, once established, F. alatamaha can live a century or more.
Franklinia alatamaha fruit develop slowly. The seed capsules require 12–14 months to mature. When ripe the pentavalved spherical capsules split above and below in a unique manner. Anecdotal evidence suggests viable seed production is enhanced where two or more plants are present in close proximity.
Franklinia alatamaha by William Bartram (1782)
Philadelphia botanists John and William Bartram first observed the tree growing along the Altamaha River near Fort Barrington in the British colony of Georgia in October 1765. John Bartram recorded "severall very curious shrubs" in his journal entry for October 1, 1765. William Bartram returned several times to the same location on the Altamaha during a collecting trip to the American South, funded by Dr. John Fothergill of London. William Bartram collected F. alatamaha seeds during this extended trip to the South from 1773 through 1776, a journey described in his book Bartram's Travels published in Philadelphia in 1791. William Bartram brought seed back to Philadelphia in 1777 at which time William reported to his father that he had relocated the plant, but this time had been able to retrieve its seeds although it was not until after John's death (1777) that he was able to achieve flowering plants (1781). After several years of study, William Bartram assigned the "rare and elegant flowering shrub" to a new genus Franklinia, named in honor of his father's great friend Benjamin Franklin. The new plant name, Franklinia alatamaha, was first published by a Bartram cousin, Humphry Marshall, in 1785 in his catalogue of North American trees and shrubs entitled Arbustrum Americanum. (Marshall 1785: 48-50; Fry 2001).
William Bartram was the first to report the extremely limited distribution of Franklinia. "We never saw it grow in any other place, nor have I ever since seen it growing wild, in all my travels, from Pennsylvania to Point Coupe, on the banks of the Mississippi, which must be allowed a very singular and unaccountable circumstance; at this place there are two or 3 acres (12,000 m2) of ground where it grows plentifully." (W. Bartram 1791: 468).
The tree was last verified in the wild in 1803 by the English plant collector John Lyon, (although there are hints it may have been present into at least the 1840s.).[6] The cause of its extinction in the wild is not known, but has been attributed to a number of causes including fire, flood, overcollection by plant collectors, and fungal disease introduced with the cultivation of cotton plants.[7]
All the Franklin trees known to exist today are descended from seed collected by William Bartram and propagated at Bartram's Garden in Philadelphia. It has now been cultivated in excess of 1000 sites worldwide.[8]
Cultivation[edit]
The Franklin tree has a reputation among gardeners for being difficult to cultivate, especially in urban environments. It prefers sandy, high-acid soil, and does not tolerate compacted clay soil, excessive moisture, or any disturbance to its roots. The Franklin tree has no known pests, but it is subject to a root-rot disease and does not endure drought well.[9]
Leaf closeup
Trunk bark
Fruit capsule
Wikimedia Commons has media related to Franklinia alatamaha.
Wikispecies has information related to Franklinia alatamaha
^ Rivers, M.C. (2015). "Franklinia alatamaha". The IUCN Red List of Threatened Species. IUCN. 2015: e.T30408A62077322. doi:10.2305/IUCN.UK.2015-2.RLTS.T30408A62077322.en. Retrieved 5 December 2017.
^ a b c Franklinia alatamaha was originally described and published in Arbustrum Americanum: The American Grove, or, an Alphabetical Catalogue of Forest Trees and Shrubs, Natives of the American United States, Arranged according to the Linnaean System. Philadelphia. 49 (-50). 1785. "Franklinia alatamaha". Germplasm Resources Information Network (GRIN). Agricultural Research Service (ARS), United States Department of Agriculture (USDA). Retrieved November 20, 2012.
^ Tsou, Chih-Hua. 1998. "Early Floral Development of Camellioideae (Theaceae)," American Journal of Botany, 85(11), p. 1531-1547.
^ Orton, Elwin R., Jr. 1977. "Successful Hybridization of Gordonia lasianthus (L.) Ellis x Franklinia alatamaha Marshall," American Association of Botanical Gardens and Arboreta, vol. 11, no. 4 (October), p. 81-84.
^ Ranney, Thomas G. and Thomas A. Eaker, Paul R. Frantz, Clifford R. Parks. 2003 "xSchimlinia floridbunda (Theaceae): A New Intergeneric Hybrid between Franklinia alatamaha and Schima argentea," HortScience, vol. 38(6), October, p. 1198-1200.
^ Bozeman, John R. and George A. Rogers. 1986. "'This very curious tree': Despite years of searching and research the enigma of Franklinia alatamaha endures," Tipularia, (November), p. 9-15.
^ Dirr, Michael A. 1998. Manual of Woody Landscape Plants: Their Identification, Ornamental Characteristics, Culture, Propagation and Uses. Stipes Publishing L.L.C.: Champaign, IL.
^ Bartram's Garden (Philadelphia, Pa., USA), "The Franklinia Story," http://www.bartramsgarden.org/franklinia/index.html, accessed 1 July 2007.
^ U.S. Forest Service, "Franklinia Alatamaha, Franklin-Tree," Fact Sheet ST-260, November 1993.
Bartram, William. 1791. Travels Through North & South Carolina, Georgia, East & West Florida,…. James & Johnson: Philadelphia.
Fry, Joel T. 2000. "Franklinia alatamaha, A History of that 'Very Curious' Shrub, Part 1: Discovery and Naming of the Franklinia", Bartram Broadside, (Spring), p. 1-24.
Marshall, Humphry. 1785. Arbustrum Americanum. The American Grove, or an Alphabetical Catalogue of Forest Trees and Shrubs, Natives of the American United States, Arranged According to the Linnaean System…, Joseph Cruikshank: Philadelphia.
USDA Plants Profile for Franklinia alatamaha (Franklin tree)
Bartram's Garden: Franklinia
Treetrail.net: Franklinia Article and Photos
entry in New Georgia Encyclopedia
Del Tredici, Peter. "Against All Odds: Growing Franklinia in Boston." Arnoldia 63 (4) (2005).
Taxon identifiers
Wikidata: Q1445326
Wikispecies: Franklinia alatamaha
ARKive: franklinia-alatamaha
EPPO: FRKAL
FNA: 220005345
GRIN: 274
iNaturalist: 141621
IRMNG: 11271436
IUCN: 30408
MoBotPF: 287338
NCBI: 182302
Plant List: kew-2814310
PLANTS: FRAL
POWO: urn:lsid:ipni.org:names:105657-2
Tropicos: 31600168
Retrieved from "https://en.wikipedia.org/w/index.php?title=Franklinia&oldid=873281726"
IUCN Red List extinct in the wild species
Endemic flora of the United States
Endemic flora of Georgia (U.S. state)
Trees of the Southeastern United States
Plants extinct in the wild
Extinct flora of North America
Monotypic Ericales genera


Heltor Chasca, Poacher, nickyboy and 1 other person like this.
Came across a small Slow Worm sunning itself on Baggy Point, North Devon this morning.
Katherine, Illaveago, Heltor Chasca and 5 others like this.
Actually, Madeira does have its own endemic pigeon species, the Trocaz Pigeon, which I've seen, fleetingly, on previous visits, but it's a bugger to photograph, and for various reasons, including the difficulty of of rousing Mrs Poacher before about 8:30 in time to catch a bus to the north of the island, I didn't even get to the relevant areas on this holiday. Here's a distant shot of a female Kestrel around the grounds of the hotel complex.
Illaveago, Heltor Chasca, booze and cake and 7 others like this.
I found this little character wandering around in my office, think I've woken her up.
Katherine, Illaveago and Heltor Chasca like this.
I saw a fox this morning near the space centre. First one I have seen for a long long time.
Katherine and Illaveago like this.
We get foxes all the time, night or day. But I did manage to see a kingfisher and a fox at the same time in pretty much the same place. I'm going back at low tide tomorrow for the kingfisher.
We used to see them pretty much every day, but for whatever reason a couple of years ago they all seemed to disappear.
Deptford at low tide. I saw this one yesterday but didn't have a camera with me so I returned today.
Katherine, albal, potsy and 8 others like this.
its always a joy to see a Kingfisher, for the first time in my life I seen one catch a fish a few weeks ago - i was watch it sat on a branch like yours, then it suddenly dived into the water then reappeared back on the branch with a little fish, she twizzled it about in her beak then swallowed it head first.
Illaveago, booze and cake and deptfordmarmoset like this.
You're right about the environment - it's in Deptford, only a few hundred miles from the A2, in a narrow park that's sandwiched between the Docklands Light Railway and an A road. I have seen them right down by the mouth of the river Thames but over the last couple of days I've not seen it go that far - it's gone to the downstream end of the park, then returned to the same perch before flying back upstream. To see them in what counts as inner city London adds to the pleasure because it seems such an unlikely place, and the river has a few fairly long tunnel stretches that they must have learned to navigate.
Illaveago and booze and cake like this.
I got the same sense of shock and delight when I saw a seal sunbathing on the banks of the Thames last year, I did not expect to see a seal in central London when I set of for a bike ride that day, seeing things where you least expect makes it extra special .
I've been there 3 times since last Friday, around late morning/midday and each time I've seen it. I only wish I had a proper camera because it's at the limit of my compact's range. If there's anyone local with a decent camera lens, I'd be happy to show them its favourite perch in the park.
I'm back in Perth for a few weeks and there is a colony of Rainbow Bee-eaters that migrate down here for the summer to breed. They nest in tunnels in the ground and return to the same spots every year. The area is well signposted to avoid the nests but apart from that is busy with families and dog walkers but the bee-eaters don't seem at all bothered - they just go about their normal business.
Pat "5mph", GM, Katherine and 8 others like this.
Around here they seem to like sitting in Oak trees and can be easily spotted perched on the end of a branch.


My first full week of summer break started on Monday! I have been busy cleaning, organizing and spending time with my kids! Have a Happy Thursday!
Amen to that though I don't have as much of it as I need. I am ready for swimming to be done.
I homeschool year round, but we scale back during summer, so I too am thankful for the extra hours of calm I get during the hot months!
It's nice to meet you! I'm following!


text:
Category: iPhone 14
All iPhone 14 models to come with 120Hz LTPO OLED displays
We have been expecting to get LTPO displays in an iPhone for quite a while, and it seems that we are finally going to get this feature in the Pro models of the upcoming iPhone 13 lineup. This means that the more expensive models will finally be able to deliver 120Hz refresh rates, while the more affordable options will remain with 60Hz refresh rate displays. Now, we can't really blame Apple, as Samsung is responsible for not producing enough displays for Cupertino. However, it seems that 120Hz refresh rates will make it to every single variant in the iPhone 14 lineup, as LG may be getting ready to supply Apple with the necessary LTPO panels next year.
According to the Korean media outlet, The Elec, LG could start providing Apple with LTPO displays for next year's iPhone 14 lineup. LG could be in talks with Avaco to get the necessary LTPO panel-making equipment. However, it would still have to wait for Apple's approval for the production line. In other words, Avaco can't start shipping equipment to LG's plants until Apple approves.
Now, if LG gets its way, it may be capable of making more than enough STOP panels to supply Apple's non-Pro iPhone 14 variants, meaning that it could also take some of the orders for next year's Pro variants. This would also be a great opportunity for Apple to stop depending so much on Samsung's products, as it would help Cupertino to diversify its supply partners further.
Now, remember that these new Low-Temperature Polycrystalline Oxide panels will help the upcoming iPhone 13 Pro models be more power-efficient. It would also allow them to get always-on displays finally. And if these panels make it to every iPhone 14 variant next year, we could get the same features in the more affordable variants.
Source The Elec
Via GSM Arena
iPhone 14 to use 4nm chip, 2022 iPad Pro to use 3nm SoC
Apple is reportedly going to adopt the latest generation of fabrication process from TSMC in the second half of next year. The new chip will likely be used in the next generation of iPhones and Apple tablets, presumably the Pro lineup. The iPad Air might also be revealed in 2022, and it will have an OLED display, and could possibly be powered by the new chipset as well.
Nikkei reports that both Apple and Intel are testing the next generation of their chipsets made with the 3-nanometer fabrication process according to several sources, familiar with the matter. The new 3-nm technology is said to increase the computing performance by 10 to 15 percent, compared to the 5-nm process. Power consumption is also said to be reduced by 25 to 30 percent.
Nanometer refers to the width between the transistors on the chip. The smaller the nanometer, the more advanced and powerful the chip can be, adding more challenges and making it more expensive to produce. The most advanced chip production technology that is used in a publicly available device is TSMC's 5-nm technology, the Apple A14 Bionic chip.
Apple's iPad will likely be among the first devices to be powered by the new chipset made using the 3-nm technology, according to the sources. The new generation of iPhones, which are expected to come out in 2022 are said to be using the 4-nm technology for "scheduling reasons".
As for Intel, the new chipsets will likely make it to data centers, notebooks and a wide variety of other advanced computing products, all in an attempt to regain some market share that was lost to AMD in recent years. AMD's market share for notebook processors rose from 11 percent in 2019 to more than 20 percent last year. "Currently the chip volume planned for Intel is more than that for Apple's iPad using the 3-nanometer process," one of the sources said.
There will likely be some competition for being the first company to efficiently produce and deliver 3-nm chipset to consumers and data centers, however Apple will likely win the battle for consumers, delivering millions of iPads and iPhones in the near future.
Roland is a technology enthusiast and software engineer based in United Kingdom.


text:
Q: Use of regression equation when not all independent variables' values are known You are given a logistic regression equation that predicts the probability of having a disease dependent on whether or not three risk factors are present. For any given patient whose chance of disease you want to predict, you are able to find out whether or not they have the first two risk factors, but you have no information either way about the third. In a situation like this, is there any way the regression equation could reasonably be used?
Of course, you can't simply set the third term equal to zero, since that supposes the patient does not have the risk factor. Is there any other option? Say you know that the prevalence of the third risk factor in the patient's population is 25%. Could you set your third independent variable equal to 0.25 and then use the equation to estimate the patient's probability of disease?

A: Solution 1: Missing value is set as a special category
This is especially adapted if the variable is already categorical: like "smokes", "doesn't smoke". You add the category "missing answer". This is when you consider a missing value is informative and you want to exploit this information: something you want to analyse.
Solution 2: simple imputation (not recommended)
The values are automatically filled. Practically they are replaced by:

*

*the mean given the other known variables if continuous

*the mode given the other known variables if categorical

This is known as "regression" in https://en.wikipedia.org/wiki/Imputation_(statistics)#Single_imputation. This may create a bias and is not recommended nowadays.
Solution 3: multiple imputation
The values are also automatically filled. The method considers the missing value has a distribution given the other variables and simulates several datasets according to this distribution. For example if the variable can have values A or B, and for a line in the dataset the probability of A/B (given the other variables) is say 30%/70%, datasets are generated by picking one of A and B with these probabilities. This require a special analysis that most stat software implement. You can read more here: https://en.wikipedia.org/wiki/Imputation_(statistics)#Multiple_imputation.

A: The answer above is already very good, but I just want to clarify something about your question. It's not clear from your question whether you have any information on the third risk factor. Benoit's answer works only if the data is available for some respondents and missing for others. If you don't have any information on the variable for any of your patients, it doesn't do any good to impute missing data. You probably know that, but I just want to make sure the bases are covered!
One other option for how to deal with the missing data if you have less than 5% missings and the missing data is missing at random, is to just perform the analysis on the cases without missing data, aka listwise deletion or complete case analysis.


Drug Substitutability Case - Could This Be Another Option Following a No-Deal Brexit?
on Tuesday, 11 December 2018.
The recent NHS win against drug companies Bayer and Novartis could save the NHS hundreds of millions of pounds and will impact on the treatments available and chosen for NHS users in the future.
In 2017, 12 NHS clinical commissioning groups (CCGs) implemented a policy to offer a drug known as Avastin to people with a blindness-causing eye condition - wet age-related macular degeneration. Avastin was to be offered as a preferred treatment option instead of similar drugs Eylea and Lucentis, as it is approximately 95% cheaper and has been shown in clinical trials to be equally safe and effective.
The controversy around this policy stemmed from the fact that Avastin does not hold a marketing authorisation for use to treat the eyes ('ophthalmic' use) - it is licensed to treat cancer - although it is commonly used as such in other countries. Supply of Avastin in its usual form to treat the eyes is therefore off-license, and supply of Avastin in a form which has been compounded for ophthalmic use is unlicensed. Both Eylea and Lucentis do hold marketing authorisations for ophthalmic use. Bayer and Novartis, the respective holders of the Eylea and Lucentis marketing authorisations, made an application for judicial review to challenge the lawfulness of the CCGs' policy of preferring Avastin. Bayer and Novartis argued that supply of Avastin as an unlicensed or off-license product was unlawful.
The High Court determined that the relevant legal test to apply was whether the policy could be implemented in a way which did not lead to, permit or encourage unlawful acts. In applying this test, the Court found that each of the ways to supply Avastin for ophthalmic use (either the off-license usual product or the unlicensed compounded product) could be lawful.
Bayer and Novartis also argued that a clinician is not permitted to take account of cost at the point of prescribing. However, the High Court found that cost could and should be taken into account when deciding between various options which are of equivalent clinical effect and safety. The Court did not believe that marketing authorisations should protect the commercial interests of pharmaceutical companies in cases where "the jeopardy to the public purse is enormous". The licence holders' commercial interests should be balanced with the public benefit.
In this case, the court accepted that treating clinicians can lawfully choose an unlicensed or off-license treatment on grounds of cost. This was under the unusual circumstance that the treatment in question had been shown to be as safe and effective as the licensed treatments.
If concerns about the pharma supply chain post-Brexit are realised, the question is whether a similar approach could be adopted towards recommending and prescribing safe and effective unlicensed or off-license alternatives to drug treatments which are unavailable due to shortages?
We will be holding a PING (Pharmaceutical Industry Network Group) Conference, in association with EMIG, on 3 April 2019 just after Brexit date, on how Brexit is affecting the pharma supply chain. If you are interested in attending the event, please contact Paul Gershlick in our Pharmaceuticals and Life Sciences team on 01923 919 320.


text:
Wagner Group boss Prigozhin mocks FBI offering a reward for his arrest
By Chris King • 26 November 2022 • 18:37
Image of FBI poster offering reward for Yevgeny Prigozhin. Credit: Uranews Telegram
Wagner Group boss Yevgeny Prigozhin mocked the fact that the FBI has offered a reward for information leading to his arrest.
Wagner mercenary group boss Yevgeny Prigozhin mocked the fact that the FBI has placed him on their 'wanted' list on the internet. Today, Saturday, November 26, the head of the infamous private army responded to a media question about his attitude towards the news.
As reported today by Uranews on their Telegram channel, the FBI announced a reward for any information that contributed to his arrest.
He told them: "I feel very positive about this. Can you imagine how many ordinary people would be able to earn extra money? And I wouldn't mind it either. The only thing that's troubling is that they've been promising this money for three years, but it looks like they haven't paid anyone".
Prigozhin joked that it was easy to apprehend him because he was either at work, in the Donbas, or on the frontlines of the war zone. "Put the key in, turn it, here I am", he summarised.
The businessman caused controversy earlier this week when he arranged for a bloodied sledgehammer in a violin case to be delivered to the European Parliament. That was his response to the outcry over a video that recently circulated online showing a Wagner Group deserter being callously executed by fellow mercenaries.
In the video, a recruited convicted murderer was shown with his head taped to a pile of bricks with cling film. A sledgehammer was subsequently used to brutally smash his head in. This action is allegedly the sentence meted out to anybody who deserts from the private military organisation. Prigozhin callously described the video as showing the death of 'a dog'.
Damning reports claim massive cover-up by China, US and UK over origins of coronavirus
BREAKING NEWS: Over 800 people injured in Iran after 5.9 magnitude earthquake